Literature DB >> 18172776

Wegener's granulomatosis: the current view.

Frank Moosig1, Peter Lamprecht, Wolfgang L Gross.   

Abstract

In the last few years, substantial progress has been achieved in elucidating the pathogenesis of Wegener's granulomatosis. Several genetic risk factors have been described. The structure of the granuloma and its possible function as ectopic lymphoid tissue have been defined. Furthermore, the consecutive immunopathological reactions leading to induction of PR3-antineutrophil cytoplasmic antibodies (ANCA) and the role of ANCA itself is getting clearer. However, the initial events leading to granuloma formation are still widely unknown. Concerning therapy, the significance of the so-called biological agents (TNF-alpha-blockers, Rituximab) still has to be defined.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18172776     DOI： 10.1007/s12016-007-8067-5

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN： 1080-0549            Impact factor:   8.667


  23 in total

1.  Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.

Authors:  K G C Smith; R B Jones; S M Burns; D R W Jayne
Journal:  Arthritis Rheum       Date:  2006-09

2.  Gene polymorphisms of immunoregulatory cytokines and angiotensin-converting enzyme in Wegener's granulomatosis.

Authors:  G Muraközy; K I Gaede; B Ruprecht; O Gutzeit; M Schürmann; A Schnabel; M Schlaak; W L Gross; J Müller-Quernheim
Journal:  J Mol Med (Berl)       Date:  2001-11       Impact factor: 4.599

3.  NB1 mediates surface expression of the ANCA antigen proteinase 3 on human neutrophils.

Authors:  Sibylle von Vietinghoff; Gisela Tunnemann; Claudia Eulenberg; Maren Wellner; M Cristina Cardoso; Friedrich C Luft; Ralph Kettritz
Journal:  Blood       Date:  2007-01-23       Impact factor: 22.113

Review 4.  Controversies in small vessel vasculitis--comparing the rheumatology and nephrology views.

Authors:  Ronald J Falk; Gary S Hoffman
Journal:  Curr Opin Rheumatol       Date:  2007-01       Impact factor: 5.006

Review 5.  Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis.

Authors:  C Mukhtyar; R Luqmani
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

6.  Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Karina A Keogh; Mark E Wylam; John H Stone; Ulrich Specks
Journal:  Arthritis Rheum       Date:  2005-01

7.  Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo.

Authors:  E Csernok; M Ernst; W Schmitt; D F Bainton; W L Gross
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

8.  New genomic region for Wegener's granulomatosis as revealed by an extended association screen with 202 apoptosis-related genes.

Authors:  Peter Jagiello; Martin Gencik; Larissa Arning; Stefan Wieczorek; Erdmute Kunstmann; Elena Csernok; Wolfgang L Gross; Joerg T Epplen
Journal:  Hum Genet       Date:  2004-02-14       Impact factor: 4.132

9.  Wegener autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via the protease-activated receptor-2 pathway.

Authors:  Elena Csernok; MaiXing Ai; Wolfgang L Gross; Daniel Wicklein; Arnd Petersen; Buko Lindner; Peter Lamprecht; Julia U Holle; Bernhard Hellmich
Journal:  Blood       Date:  2006-02-14       Impact factor: 22.113

10.  Antineutrophil cytoplasmic autoantibodies interact with primary granule constituents on the surface of apoptotic neutrophils in the absence of neutrophil priming.

Authors:  H M Gilligan; B Bredy; H R Brady; M J Hébert; H S Slayter; Y Xu; J Rauch; M A Shia; J S Koh; J S Levine
Journal:  J Exp Med       Date:  1996-12-01       Impact factor: 14.307
View more
  8 in total

1.  Altered serum levels of human neutrophil peptides (HNP) and human beta-defensin 2 (hBD2) in Wegener's granulomatosis.

Authors:  Stefan Vordenbäumen; Daniel Timm; Ellen Bleck; Jutta Richter; Rebecca Fischer-Betz; Gamal Chehab; Oliver Sander; Matthias Schneider
Journal:  Rheumatol Int       Date:  2010-12-04       Impact factor: 2.631

Review 2.  Vasculitides associated with IgG antineutrophil cytoplasmic autoantibodies in childhood.

Authors:  Federica Vanoni; Alberto Bettinelli; Franco Keller; Mario G Bianchetti; Giacomo D Simonetti
Journal:  Pediatr Nephrol       Date:  2009-07-30       Impact factor: 3.714

Review 3.  [Anti-B-cell strategies in vasculitides and collagenoses].

Authors:  A Rubbert-Roth
Journal:  Z Rheumatol       Date:  2009-07       Impact factor: 1.372

4.  [Autoimmune vasculitides. Standards and guidelines of EULAR and EUVAS].

Authors:  F Moosig; J U Holle; W L Gross
Journal:  Internist (Berl)       Date:  2009-03       Impact factor: 0.743

5.  Top Differential Diagnosis Should Be Microscopic Polyangiitis in ANCA-Positive Patient with Diffuse Pulmonary Hemorrhage and Hemosiderosis.

Authors:  Nicholas D Ward; Diane E Cosner; Colleen A Lamb; Wei Li; Jacqueline K Macknis; Michele T Rooney; Ping L Zhang
Journal:  Case Rep Pathol       Date:  2014-11-30

6.  All Consolidations are not Infective: Look Beyond ARDS.

Authors:  Mohammed Ismail Nizami; M Rahul Rohan; Ashima Sharma
Journal:  J Emerg Trauma Shock       Date:  2019 Apr-Jun

7.  Successful endonasal dacryocystorhinostomy in a patient with Wegener's granulomatosis.

Authors:  P Eloy; E Leruth; B Bertrand; P H Rombaux
Journal:  Clin Ophthalmol       Date:  2009-12-29

Review 8.  Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence?

Authors:  Frank Moosig; Julia U Holle; Wolfgang L Gross
Journal:  Arthritis Res Ther       Date:  2009-10-28       Impact factor: 5.156
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.